Matinas BioPharma
MTNB
71 hedge funds and large institutions have $57.1M invested in Matinas BioPharma in 2020 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 9 closing their positions.
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
64% more capital invested
Capital invested by funds: $34.8M → $57.1M (+$22.3M)
16% more funds holding
Funds holding: 61 → 71 (+10)
0.04% less ownership
Funds ownership: 0.46% → 0.42% (-0.04%)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.13M |
| 2 |
PFMOSF
Philadelphia Financial Management of San Francisco
San Francisco,
California
|
+$686K |
| 3 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
+$609K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$582K |
| 5 |
Millennium Management
New York
|
+$362K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.47M |
| 2 |
Two Sigma Investments
New York
|
-$1.27M |
| 3 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$548K |
| 4 |
Two Sigma Advisers
New York
|
-$385K |
| 5 |
WIC
Water Island Capital
New York
|
-$268K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Ameriprise
Minneapolis,
Minnesota
| – | -$8K | -219 | Closed |
|
|
LA
77
Legacy Advisors
Plymouth Meeting,
Pennsylvania
| – | -$8K | -200 | Closed |
|
|
JC
78
JBF Capital
Aspen,
Colorado
| – | -$5K | -135 | Closed |
|
|
CAL
79
Capital Analysts LLC
Fort Washington,
Pennsylvania
| – | -$1K | -25 | Closed |
|
MTNB Hedge Fund Activity: Q4 2020 in Review
71 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2020, worth a combined $57.1M — up 64% from $34.8M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new MTNB positions and 9 closed out — a net gain of 10 holders — while 11 added to existing stakes and 15 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.13M. The largest seller was Vivo Capital, cutting an estimated $4.47M.
- 71 institutional investors held Matinas BioPharma (MTNB) as of Q4 2020, up from 61 in Q3 2020.
- Funds reported $57.1M of Matinas BioPharma stock for Q4 2020, up 64% quarter-over-quarter.
- 19 funds opened new Matinas BioPharma positions in Q4 2020 and 9 closed out, a net change of +10 holders.
- The largest Matinas BioPharma buyer in Q4 2020 was Renaissance Technologies, an estimated $1.13M added.
- The largest Matinas BioPharma seller in Q4 2020 was Vivo Capital, an estimated $4.47M sold.
Based on aggregated 13F filings for Q4 2020.